Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron Variant | Zendy

Adeel A. Butt | Zendy; Victor B. Talisa | Zendy; Obaid S. Shaikh | Zendy; Saad B. Omer | Zendy; Florian Mayr | Zendy

Open Access

Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron Variant

Author(s) -

Adeel A. Butt,

Victor B. Talisa,

Obaid S. Shaikh,

Saad B. Omer,

Florian Mayr

Publication year - 2022

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciac328

Subject(s) - medicine , booster (rocketry) , virology , covid-19 , booster dose , coronavirus , respiratory system , messenger rna , severe acute respiratory syndrome coronavirus , immunology , virus , gene , infectious disease (medical specialty) , titer , disease , biology , outbreak , biochemistry , physics , astronomy

The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may be less effective against the Omicron variant than against earlier variants. With recent resurgence of SARS-CoV-2 cases, the role of booster doses of the vaccine needs to be highlighted.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research